Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $2.52 Million - $3.36 Million
-49,300 Reduced 40.78%
71,600 $3.87 Million
Q1 2024

May 15, 2024

SELL
$60.67 - $89.12 $606,700 - $891,200
-10,000 Reduced 7.64%
120,900 $8.24 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $5.02 Million - $9.39 Million
130,100 Added 16262.5%
130,900 $8.19 Million
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $34,776 - $54,216
800 New
800 $44,000
Q4 2021

Feb 08, 2022

SELL
$70.09 - $111.29 $4.58 Million - $7.27 Million
-65,300 Reduced 28.89%
160,700 $12.2 Million
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $4.45 Million - $6.33 Million
-40,400 Reduced 15.17%
226,000 $25.3 Million
Q2 2021

Sep 13, 2021

BUY
$100.84 - $161.89 $26.9 Million - $43.1 Million
266,400 New
266,400 $43.1 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.82B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.